GlobeNewsWire
05 Mar 2026, 21:05 UTC · 29w ago
Verdict
Headline takes no side. We score NXTC +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
NextCure expects to present Phase 1 clinical dose escalation data for its SIM0505 candidate in Q2 2026.
More positive than 93% of claims this week
The company is expanding its SIM0505 program by doubling U.S. trial sites and expanding into multiple other countries.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 66% of claims this week
NextCure is initiating enrollment for platinum-resistant ovarian cancer patients in the SIM0505 Phase 1 dose optimization study.
More positive than 53% of claims this week
NextCure is currently conducting Phase 1 dose escalation enrollment for its LNCB74 (B7-H4 ADC) program.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company reports progress on its clinical trials for SIM0505 and LNCB74, with expectations for a transformational year in 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−60.2%
Price is moving against the score
$5.08 vs $12.76 close before publication (Mar 5) · not market-adjusted
NXTC chart →
